AG真人官方

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders

Aptose to hold a reconvened shareholder meeting on August 22, 2025 at 10:00 a.m. (Eastern Time) to vote on appointment of new auditor

SAN DIEGO and TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (鈥淎ptose鈥� or the 鈥淐ompany鈥�) (TSX: APS; OTC: APTOF; OTCQB: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced today that the Company鈥檚 Board of Directors (the 鈥淏oard鈥�) has unanimously approved the selection of Ernst & Young LLP (鈥淓Y鈥�) as the Company鈥檚 independent registered public accounting firm to serve as the Company鈥檚 independent auditor. The Company had previously adjourned their Annual and Special Meeting of shareholders held on May 27, 2025 (the 鈥淥riginal Meeting鈥�), for the purposes of completing its search for a successor independent auditor.

EY is a top-ranked global accounting firm that offers a complete spectrum of tax, assurance, and advisory services途 they have been selected due to their expertise, capabilities, fit, and understanding of the Company's industry and business.

The Company will reconvene its Annual General and Special Meeting of shareholders (the 鈥淩econvened Meeting鈥�) on August 22, 2025 at 10:00 a.m. (Eastern Time) to vote on the appointment of EY and the authorization of the Board to fix EY鈥檚 remuneration.

All interested parties are invited to attend the Reconvened Meeting by using the live webcast link here: . Only registered shareholders and duly appointed proxyholders as of the record date on April 22, 2025, will be entitled to vote and ask questions at the Reconvened Meeting.

Unless properly revoked, proxies previously completed, signed, dated and returned in respect of the Original Meeting will be effective at the Reconvened Meeting and shareholders do not need to vote again. New forms of proxies are not being distributed by the Company. Registered shareholders of record at the close of business on April 22, 2025, who have not previously deposited a form of proxy may deposit a properly executed form of proxy no later than 48 hours, excluding weekends and holidays, before the Reconvened Meeting, or any adjournments or postponements thereof, with Computershare Investor Services Inc. (i) via the internet at: ; (ii) by phone at: 1-866-732-VOTE (8683); or (iii) by mail to Computershare Investor Services Inc., 320 Bay Street, 14th Floor, Toronto, Ontario, M5H 4A6. Copies of the proxy statement and form of proxy have been filed on SEDAR+ and are available electronically at . Beneficial shareholders who wish to vote must follow the procedures and instructions received from their brokers or other intermediaries, and contact their brokers or other intermediaries if they need assistance.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company鈥檚 lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit .

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including statements relating but not limited to, the appointment of a new independent auditor of the Company, the date and time of the Reconvened Meeting, the development of tuspetinib, and statements relating to the Company鈥檚 plans, objectives, expectations and intentions and other statements including words such as 鈥渃ontinue鈥�, 鈥渆xpect鈥�, 鈥渋ntend鈥�, 鈥渨ill鈥�, 鈥渟hould鈥�, 鈥渨ould鈥�, 鈥渕ay鈥�, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to appoint a new independent auditor, our ability to hold the Reconvened Meeting and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 鈥淩isk Factors鈥� in our filings with Canadian securities regulators underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

For further information, please contact:

Aptose Biosciences Inc. 聽聽聽聽聽聽聽聽 聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽
Susan Pietropaolo 聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽
Corporate Communications & Investor Relations 聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽
201-923-2049听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听